Medrad has signed a distribution and co-marketing partnership agreement with Petnet Solutions, a fully owned subsidiary of Siemens Medical Solutions USA.
Subscribe to our email newsletter
The agreement will enable health care providers to inject Fluorodeoxyglucose (FDG) for positron emission tomography/computed tomography (PET/CT) imaging procedures in a new way.
The partnership will leverage Medrad’s soon to be introduced Pet infusion system and multi-dose FDG packaging and delivery from Petnet Solutions. PET/CT Imaging is said to be effective in diagnosing and staging certain forms of cancer.
Petnet Solutions has agreed to provide FDG to customers throughout its extensive, cyclotron-based radiopharmacy network in multi-dose vials and specially designed vial shields, which will allow for easy integration with Medrad’s new system.
Alan Connor, director of global marketing for molecular imaging at Medrad, said: “We are very pleased that Petnet Solutions is the first FDG provider to agree to provide FDG in a manner compatible with the Intego System across its entire network.”
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.